Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Investors purchased 4,063 put options on the company. This is an increase of 2,362% compared to the average volume of 165 put options.
Xenon Pharmaceuticals Stock Up 0.4 %
Xenon Pharmaceuticals stock traded up $0.18 during midday trading on Thursday, reaching $42.15. The company's stock had a trading volume of 80,495 shares, compared to its average volume of 384,703. The company has a market cap of $3.19 billion, a P/E ratio of -14.91 and a beta of 1.25. The business has a 50-day simple moving average of $41.14 and a 200-day simple moving average of $40.35. Xenon Pharmaceuticals has a fifty-two week low of $28.10 and a fifty-two week high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same quarter in the previous year, the company posted ($0.73) EPS. As a group, equities analysts forecast that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on XENE shares. Wedbush reduced their price target on Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating for the company in a report on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 target price on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. William Blair raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Needham & Company LLC restated a "buy" rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. Eleven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $57.45.
Read Our Latest Research Report on Xenon Pharmaceuticals
Institutional Trading of Xenon Pharmaceuticals
Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in shares of Xenon Pharmaceuticals by 89.5% during the first quarter. BNP Paribas Financial Markets now owns 8,321 shares of the biopharmaceutical company's stock worth $358,000 after acquiring an additional 3,931 shares during the period. SG Americas Securities LLC increased its position in Xenon Pharmaceuticals by 9.5% during the 1st quarter. SG Americas Securities LLC now owns 20,366 shares of the biopharmaceutical company's stock worth $877,000 after purchasing an additional 1,760 shares during the period. Oppenheimer Asset Management Inc. raised its stake in shares of Xenon Pharmaceuticals by 21.4% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 5,374 shares of the biopharmaceutical company's stock worth $231,000 after buying an additional 946 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Xenon Pharmaceuticals by 2.2% in the 1st quarter. Russell Investments Group Ltd. now owns 178,099 shares of the biopharmaceutical company's stock valued at $7,667,000 after buying an additional 3,813 shares during the period. Finally, ProShare Advisors LLC boosted its stake in shares of Xenon Pharmaceuticals by 12.0% in the first quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company's stock valued at $228,000 after buying an additional 565 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Recommended Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
